Physician profile
Jesse E Robinson
NPI 1760110266
$4,602.45
in general payments reported to CMS, 2019-2025
24 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $292 · 2023: $1,416 · 2024: $1,581 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,310.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,107.63 | 2022-2025 | |
| Ucb, INC. | $639.13 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $628.86 | 2023-2025 | |
| Biogen, INC. | $449.88 | 2022-2025 | Vumerity, Tysabri, Plegridy |
| Lilly USA, LLC | $383.05 | 2022-2025 | Emgality, Amyvid, Kisunla |
| Lundbeck LLC | $208.89 | 2023-2025 | Vyepti |
| Mdd US Operations, LLC | $180.65 | 2023-2024 | Gocovri, Gocovri |
| Genentech USA, INC. | $151.41 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $122.53 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $119.02 | 2023-2024 | Aptiom |
| Eisai INC. | $111.87 | 2024-2025 | |
| Csl Behring | $86.21 | 2023-2024 | Hizentra |
| Amneal Pharmaceuticals LLC | $80.45 | 2022-2025 | Crexont, Rytary |
| Teva Pharmaceuticals USA, INC. | $66.55 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Octapharma USA, INC. | $36.95 | 2024 | Panzyga |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $36.21 | 2023 | Trudhesa |
| Alexion Pharmaceuticals, INC. | $35.47 | 2022-2023 | Ultomiris |
| Neurocrine Biosciences, INC. | $33.63 | 2024-2025 | Ingrezza |
| Neurelis, INC. | $31.54 | 2025 | Valtoco |
| Impel Pharmaceuticals LLC | $24.02 | 2025 | Trudhesa |
| Acadia Pharmaceuticals INC | $21.79 | 2023 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.76 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $15.15 | 2023 | Andexxa |
| Boston Scientific Corporation | $13.80 | 2025 | General - Dbs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.